HIGHLIGHTS
SUMMARY
Chimeric antigen receptor (CAR)-T_cell therapy experienced tremendous progress in the last decade as an effective strategy targeting B cell malignancies and multiple myeloma. Major hindrances still need to be faced to improve CAR-T_cell efficacy, especially against solid tumors. Clinical benefits are in part limited by a tumor microenvironment (TME) presenting physical, functional and dynamic barriers that hamper CAR-T_cell infiltration and by immune suppressive mechanisms that dampen their function. The authors designed such construct to be inducible upon T_cell activation to successfully downregulate PD-1 gene_expression, a system referred to as CRISPR . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.